蔣維棠

WT Jiaang 2蔣維棠  研究員
生技與藥物研究所
Email: wtjiaang@nhri.edu.tw

 

EDUCATION

  • Ph.D., Organic Chemistry, National Taiwan University, Taipei, Taiwan (1996)
  • M.S., Organic Chemistry, Tamkang University, Taipei, Taiwan (1991)
  • B.S., Chemistry, Tamkang University, Taipei, Taiwan (1989)

PROFESSIONAL EXPERIENCES

  • Acting Associate Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (2022)
  • Associate Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes (2020- 2022)
  • Investigator, Institute of Biotechnology and Pharmaceutical Research, NHRI (2011-present)
  • Associate Investigator, Division of Biotechnology and Pharmaceutical Research, NHRI (2006-2011)
  • Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, NHRI (2002-2006)
  • Investigator, Union Chemical Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan (2000-2002)
  • Postdoctoral Fellow, Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan (1996-2000)

RESEARCH INTERESTS

Dr. Jiaang’s research interests include organic synthesis, medicinal chemistry, radical chemistry, carbohydrate chemistry, peptide synthesis, and photopolymer chemistry for Integrated Circuit (IC) and Flat Panel Display (FPD). A main current focus of his research is the discovery and development of anti-diabetes and anti-cancer drugs.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

At NHRI, Dr. Jiaang’s first project focused on the discovery of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type II diabetes. In this project, Dr. Jiaang has successfully identified a potent and selective DPP-IV inhibitor, DBPR108, currently in clinical development. Currently, Dr. Jiaang is developing new anti-cancer drugs, such as FLT3 inhibitors for the treatment of acute myeloid leukemia. Dr. Jiaang has 38 publications related to his research areas in organic, medicinal and polymer chemistry in SCI journals and has awarded five US patents.

SELECTED PUBLICATIONS (2011~2021)

  1. Kai-Chia Yeh, Teng-Kuang Yeh, Chung-Yu Huang , Chih-Bo Hu, Min-Hsien Wang, Yu-Wen Huang, Ling-Hui Chou, Hsuan-Hui Ho, Jen-Shin Song, Tsu Hsu, Weir-Torn Jiaang, Yu-Sheng Chao, Chiung-Tong Chen. DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. Life Sci. 2021, 278, 119574.
  2. Lung-Chun Lee, Yi-Hui Peng, Hsin-Huei Chang, Tsu Hsu, Cheng-Tai Lu, Chih-Hsiang Huang, Ching-Cheng Hsueh, Fang-Chun Kung, Ching-Chuan Kuo*, Weir-Torn Jiaang*, Su-Ying Wu*. Xanthine Derivatives Reveal an Allosteric Binding Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2). J. Med. Chem. 2021, 64, 11288-11301.
  3. Zheng-Sheng Lai, Teng-Kuang Yeh, Yu-Chi Chou, Tsu Hsu, Cheng-Tai Lu, Fang-Chun Kung, Ming-Yen Hsieh, Chun-Hung Lin, Chiung-Tong Chen, Che-Kun James Shen*, Weir-Torn Jiaang*. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease. Eur. J. Med. Chem. 2021, 209, 112938.
  4. Wen-Hsing Lin, Su-Ying Wu, Teng-Kuang Yeh,1, Chiung-Tong Chen, Jen-Shin Song, Hui-Yi Shiao, Ching-Chuan Kuo, Tsu Hsu, Cheng-Tai Lu, Pei-Chen Wang, Tsung-Sheng Wu, Yi-Hui Peng, Hui-You Lin, Ching-Ping Chen, Ya-Ling Weng, Fang-Chun Kung, Mine-Hsine Wu, Yu-Chieh Su, Kuo-Wei Huang, Ling-Hui Chou, Ching-Cheng Hsueh, Kuei-Jung Yen, Po-Chu Kuo, Chen-Lung Huang, Li-Tzong Chen, Chuan Shih, Hui-Jen Tsai*, and Weir-Torn Jiaang*. Identification of a multitargeted tyrosine kinase inhibitor for the treatment of gastrointestinal stromal tumors (GISTs) and acute myeloid leukemia (AML). J. Med. Chem. 2019, 62, 11135-11150.
  5. Tsung-Sheng Wu, Wen-Hsing Lin, Hui-Jen Tsai, Ching-Cheng Hsueh, Tsu Hsu, Pei-Chen Wang, Hui-You Lin, Yi-Hui Peng, Cheng-Tai Lu, Lung-Chun Lee, Chih-Hsiang Tu, Fang-Chun Kung, Hui-Yi Shiao, Teng-Kuang Yeh, Jen-Shin Song, Jia-Yu Chang, Yu-Chieh Su, Li-Tzong Chen, Chiung-Tong Chen, Weir-Torn Jiaang*, and Su Ying Wu*. Discovery of conformational control inhibitors switching off the activated c-KIT and targeting a broad range of clinically relevant c-KIT mutants. J. Med. Chem. 2019, 62, 3940–3957.
  6. Han-Syuan Lin, Yi-Luen Huang, Yi-Rui Stefanie Wang, Eugene Hsiao, Tsu-An Hsu, Hui-Yi Shiao, Weir-Torn Jiaang, Bonifasius Putera Sampurna, Kuan-Hao Lin, Ming-Shun Wu, Gi-Ming Lai, and Chiou-Hwa Yuh*. Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform. Cancers 2019, 11, 739.
  7. Hui‐Jen Tsai*, Weir‐Torn Jiaang, Neng‐Yao Shih, Jonathan A. Fletcher, Ming‐Jon Lin, Ming‐Yu Yang, Chiung‐Tong Chen, Tsu‐An John Hsu, Chun‐Chieh Wu, Hui‐You Lin, and Li‐Tzong Chen. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. Cancer Sci. 2018, 109, 3591–3601.
  8. Li-Tzong Chen†, Chiung-Tong Chen†, Weir-Torn Jiaang†, Tsai-Yun Chen, Joseph H. Butterfield, Neng-Yao Shih, John Tsu-An Hsu, Hui-You Lin, Sheng-Fung Lin, and Hui-Jen Tsai*. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT–driven myeloid leukemia. Mol. Cancer Ther. 2016, 15, 2323-2333.
  9. Chih-Hsiang Tu, Wen-Hsing Lin, Yi-Hui Peng, Tsu Hsu, Jian-Sung Wu, Chun-Yu Chang, Cheng-Tai Lu, Ping-Chiang Lyu, Chuan Shih, Weir-Torn Jiaang*, and Su-Ying Wu*. pyrazolylamine derivatives reveal the conformational switching between Type I and Type II binding modes of anaplastic lymphoma kinase (ALK). J. Med. Chem.2016, 59, 3906-3919.
  10. Chiung-Tong Chen, John T.-A. Hsu, Wen-Hsing Lin, Cheng-Tai Lu, Shih-Chieh Yen, Tsu Hsu, Yu-Ling Huang, Jen-Shin Song, Chun-Hwa Chen, Ling-Hui Chou, Kuei-Jung Yen, Ching-Ping Chen, Po-Chu Kuo, Chen-Lung Huang, H. Eugene Liu, Yu-Sheng Chao, Teng-Kuang Yeh*, and Weir-Torn Jiaang*. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations. Eur. J. Med. Chem. 2015, 100, 151-161.
  11. Wen-Hsing Lin†, Teng-Kuang Yeh†, Weir-Torn Jiaang†, Kuei-Jung Yen, Chun-Hwa Chen, Chin-Ting Huang, Shih-Chieh Yen, Shu-Yi Hsieh, Ling-Hui Chou, Ching-Ping Chen, Chun-Hsien Chiu, Li-Chun Kao, Yu-Sheng Chao, Chiung-Tong Chen*, and John T.-A. Hsu*. Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer. PLoS One. 2014, 9, e83160.
  12. John T.-A. Hsu, Teng-Kuang Yeh, Shih-Chieh Yen, Chiung-Tong Chen, Shu-Yi Hsieh, Tsu Hsu, Cheng-Tai Lu, Chun-Hwa Chen, Ling-Hui Chou, Ching-Hui Chiu, Yun-I Chang, Ya-Ju Tseng, Kuei-Rong Yen, Yu-Sheng Chao, Wen-Hsing Lin*, and Weir-Torn Jiaang*. 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorg. Med. Chem. Lett. 2012, 22, 4654-4659.
  13. Wen-Hsing Lin†, Weir-Torn Jiaang†, Kuei-Rong Yen, Tsu Hsu, Ching-Ping Chen, Kai-Yen Chang, Chun-Wha Chen, Chung-Yu Chang, Yu-Sheng Chao, Chiung-Tong Chen*, and John T.-A. Hsu*. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br. J. Cancer. 2012, 106, 475-481.
  14. Tsu Hsu, Ting-Yueh Tsai, Ya-Ju Tseng, Mei-Chun Chiou, Cheng-Tai Lu, Yu-Sheng Chao, and Weir-Torn Jiaang*. “Synthesis of 3,3-Dimethylglutamic Acid Derivatives as DPP-IV Inhibitors and Evaluation of Their Chemical Stability. J. Chin. Chem. Soc., 2011, 58, 1-10.
  15. Chih-Hsiang Huang, Ching-Shu Suen, Ching-Ting Lin, Chia-Hui Chien, Hsin-Ying Lee, Kuei-Min Chung, Ting-Yueh Tsai, Weir-Tong Jiaang, Ming-Jing Hwang, and Xin Chen*. “Cleavage-site Specificity of Prolyl Endopeptidase FAP Investigated with a Full-Length Protein Substrate” J. Biochem. 2011, 149, 685-692.
  16. Shu-Jen Chen, Weir-Torn Jiaang*. “Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein” Curr. Top. Med. Chem. 2011, 1447-1463.
  17. Wen-Hsing Lin, Shu-Yi Hsieh, Shih-Chieh Yen, Chiung-Tong Chen, Teng-Kuang Yeh, Tsu Hsu, Cheng-Tai Lu, Ching-Ping Chen, Chun-Wha Chen, Ling-Hui Chou, Yu-Lin Huang, An-Huei Cheng, Yun-I Chang, Ya-Ju Tseng, Kuei-Rong Yen, Yu-Sheng Chao, John T.-A. Hsu*, and Weir-Torn Jiaang*. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorg. Med. Chem. 2011, 19, 4173-4182.

PATENT

  1. 專利名稱：Aminothiazole compounds as protein kinase inhibitors (作為蛋白激酶抑制劑的胺基噻唑化合物)，申請日：2017/6/13，國別：美國、中華民國與PCT (13國及歐盟)，專利狀態：美國與中華民國獲證。
  2. 專利名稱：Aminothiazole compounds and use thereof (氨基噻唑化合物及其用途)，申請日：2016/2/5，國別：美國、中華民國與PCT (3國及歐盟)，專利狀態：美國與中華民國獲證。
  3. 專利名稱：Pyrazole compounds and thiazole compounds as protein kinases inhibitors (作為蛋白質機酶抑制劑之吡唑化合物及噻唑化合物)，申請日：2011/3/4，國別：美國與中華民國，專利狀態：獲證。
  4. 專利名稱：Pyrrolidine Derivatives (吡咯啉啶化合物)，申請日：2009/3/19，國別：美國、中華民國與PCT (12國及歐盟)，專利狀態：獲證。
  5. 專利名稱：Pyrrolidinecompounds (吡咯啉啶化合物)，申請日：2004/3/9，國別：美國、中華民國與PCT (4國及歐盟)，專利狀態：獲證。

技術轉移

  1. 技術名稱：新穎抗糖尿病候選藥物DBPR108，授權單位：國家衛生研究院，被授權單位：健亞生物科技，簽約日期：2012.11.30。
  2. 技術名稱：酪胺酸激酶抑制劑DBPR216治療胃腸道基質瘤與治療急性骨髓白血病，授權單位：國家衛生研究院，被授權單位：泰緯生命科技，簽約日期：2019.04.08。

Comments are closed.